These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33508757)

  • 1. Phage display screening identifies a prostate specific antigen (PSA)
    Sui Y; Zhu R; Hu W; Zhang W; Zhu H; Gong M; Gao L; Cao T; Tang T; Yu B; Yang T
    Transl Oncol; 2021 Mar; 14(3):101020. PubMed ID: 33508757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
    Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
    Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.
    Qin J; Liu X; Laffin B; Chen X; Choy G; Jeter CR; Calhoun-Davis T; Li H; Palapattu GS; Pang S; Lin K; Huang J; Ivanov I; Li W; Suraneni MV; Tang DG
    Cell Stem Cell; 2012 May; 10(5):556-69. PubMed ID: 22560078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
    Liu X; Chen X; Rycaj K; Chao HP; Deng Q; Jeter C; Liu C; Honorio S; Li H; Davis T; Suraneni M; Laffin B; Qin J; Li Q; Yang T; Whitney P; Shen J; Huang J; Tang DG
    Oncotarget; 2015 Sep; 6(27):23959-86. PubMed ID: 26246472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.
    Chen X; Li Q; Liu X; Liu C; Liu R; Rycaj K; Zhang D; Liu B; Jeter C; Calhoun-Davis T; Lin K; Lu Y; Chao HP; Shen J; Tang DG
    Clin Cancer Res; 2016 Sep; 22(17):4505-16. PubMed ID: 27060154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Sui Y; Hu W; Zhang W; Li D; Zhu H; You Q; Zhu R; Yi Q; Tang T; Gao L; Zhu S; Yang T
    Br J Cancer; 2021 Sep; 125(7):1003-1015. PubMed ID: 34247196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients.
    Sasaki T; Sugimura Y
    J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30567361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
    Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
    Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
    [No Abstract]   [Full Text] [Related]  

  • 19. Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.
    Mahajan NP; Coppola D; Kim J; Lawrence HR; Lawrence NJ; Mahajan K
    Sci Rep; 2018 Jan; 8(1):1954. PubMed ID: 29386546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.